Mark M. Moasser

Mark M. Moasser, MD, is a Clinical Professor in the Department of Medicine at the University of California, San Francisco (UCSF), where he specializes in Breast Medical Oncology at the UCSF Breast Care Center. He is actively involved in both clinical care and translational research, focusing on developing novel therapies for breast cancer and leading innovative clinical trials.

Education:

• Medical Degree: Tufts University School of Medicine, 1988
• Internship: NewYork-Presbyterian Hospital, 1989
• Residency: NewYork-Presbyterian Hospital, 1991
• Fellowship: Memorial Sloan Kettering Cancer Center, 1996

Dr. Moasser’s research focuses on molecular pathways in cancer, particularly HER2 signaling and drug resistance mechanisms. His work bridges laboratory discoveries with clinical applications, aiming to improve outcomes for patients with advanced breast and other cancers. He investigates inflammatory signaling programs and combination therapies to overcome resistance to targeted agents.

His recent publications highlight trends in targeted therapy resistance, combination chemotherapy, and molecular oncology, particularly in breast and colorectal cancers. These studies reflect a strong emphasis on translational research, biomarker discovery, and clinical trial design.

Scientific Awards:

• No specific awards listed in the provided text.

Dr. Moasser is actively involved in mentoring and clinical training through his role at a leading academic cancer center. While specific grants are not listed, his leadership in clinical trials and published research suggests ongoing funded research activity. He is board-certified in Medical Oncology by the American Board of Internal Medicine (1995).

He is affiliated with the Breast Care Center at UCSF, where he leads research initiatives and provides patient care. His lab and research team focus on identifying and overcoming resistance mechanisms in cancer therapy, particularly through SRC and COX2 pathways.